<DOC>
	<DOC>NCT00758966</DOC>
	<brief_summary>The purpose of this study is to determine if the combination of naltrexone SR and fluoxetine is more effective in treating the symptoms of obsessive-compulsive disorder (OCD)than either fluoxetine alone or naltrexone SR alone.</brief_summary>
	<brief_title>Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Male or female subjects, 18 to 60 years of age (inclusive) Outpatients with a current diagnosis of OCD that have received previous therapy Negative serum pregnancy test as screening in women of childbearing potential If a woman of childbearing potential, must agreed to use an acceptable and effective form of contraception No clinically significant abnormality on electrocardiogram (ECG) No clinically significant laboratory abnormality at screening Negative urine drug screen Must be considered reliable and possess a level of understanding that enables the subject to provide written informed consent and to comply with protocol procedures and schedule Diagnosis of substance dependence Diagnosis of substance abuse (except for nicotine and caffeine) Serious or unstable medical illnesses Lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, anorexia nervosa, Pervasive Developmental Disorder (PDD), Asperger's Syndrome or the presence of antisocial or borderline personality disorder Diagnosis of tic disorder or Tourette's Syndrome Subjects diagnosed with impulse control disorder Known sensitivity or allergic reaction to either naltrexone or fluoxetine Any condition which in the opinion of the investigator or Sponsor makes the subject unsuitable for inclusion in the study Immediate family of investigators, study personnel or Sponsor representatives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>OCD,</keyword>
	<keyword>naltrexone,</keyword>
	<keyword>fluoxetine,</keyword>
	<keyword>obsessive-compulsive disorder</keyword>
</DOC>